https://www.selleckchem.com/products/azd2014.html
rgence of on-target resistance, which may provide guidance for clinical decision making. Sequential postprogression plasma profiling revealed that increased lines of ALK inhibitors can accelerate the accumulation of ALK resistance mutations and may lead to treatment-refractory compound ALK mutations. The selection for optimal first-line TKI is very important to achieve a more efficacious long-term strategy and prevent the emergence of on-target resistance, which may provide guidance for clinical decision making.Mutigenerational studies
Like
Comment
Share
